Andrew Cheng, Akero Therapeutics CEO

Akero’s NASH can­di­date re­duces liv­er fat in pa­tients tak­ing a GLP-1

Akero Ther­a­peu­tics said its NASH drug re­duced liv­er fat in pa­tients who were al­so tak­ing a GLP-1 ag­o­nist.

The NASH-fo­cused biotech on Mon­day re­leased topline da­ta from a Phase IIb tri­al for 32 pa­tients with type 2 di­a­betes and F1-F3 liv­er fi­bro­sis due to NASH who par­tic­i­pat­ed in the SYM­ME­TRY study for 12 weeks. Liv­er fi­bro­sis is scored based on how pro­gres­sive it is; F1 fi­bro­sis is in­dica­tive of min­i­mal scar­ring, while F3 is typ­i­cal­ly seen as se­vere.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.